Navigation Links
New drug treatment extends lives of men with prostate cancer
Date:5/26/2011

AURORA, Colo. (May 25, 2011) - A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months. The study in the May 26, 2011 issue of the New England Journal of Medicine was co-authored by Thomas W. Flaig, MD, medical oncologist at the University of Colorado Hospital's Tony Grampsas Urologic Oncology Clinic and assistant professor at the University of Colorado School of Medicine.

"Abiraterone acetate is a new, life-extending pill for the treatment of advanced prostate cancer. Unlike the traditional chemotherapy drugs used in these situations, abiraterone is generally very well tolerated," said Flaig.

The multi-center Phase III clinical trial of 1195 participants looked at the effectiveness of treating patients who had received prior chemotherapy with a combination of abiraterone acetate (ZytigaTM ) and prednisone. When this trial was initiated, there were no treatments that clearly prolonged survival in this late phase of prostate cancer. The patients were randomized to receive abiraterone acetate plus prednisone or a placebo plus prednisone each day. Treatment continued until the cancer progressed, there were unfavorable reactions, a new treatment was initiated or the patient withdrew from the trial.

The study shows participants taking abiraterone acetate lived about four months longer than participants taking the placebo. In addition, more patients receiving abiraterone acetate experienced a significant drop in the PSA blood level than those on the placebo.

"The survival benefit observed in this study is especially notable, since this was seen in the most advanced cases of prostate cancer," said Flaig. "Other studies are being done to examine the benefit of using abiraterone acetate earlier in the disease process, where it may be even more effective."

The FDA approved abiraterone acetate at the end of April. The tablet has few side effects but careful medical attention is required to monitor for specific potential side effects including liver blood test changes, low potassium levels, leg swelling and high blood pressure.


'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
720-848-7852
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy
2. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
3. US study shows that tofacitinib is an efficacious treatment for active RA
4. Research suggests that lipofilling may be safe during conservation treatment for breast cancer
5. New study aims to improve long-term treatment for patients with bipolar disorder
6. PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients
7. IUPUI study first to look at early treatment of depression to reduce heart disease risk
8. Mount Sinai researchers discover possible new target for sarcoma treatment and prevention
9. Quicker detection and treatment of severe sepsis
10. Substantial recovery rate with placebo effect in headache treatment
11. Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the official ... Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony on ... of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than 1,400 ...
(Date:3/28/2017)... ... 2017 , ... For many women, getting birth control isn’t as easy as it should be. ... have access to a health care facility or a pharmacy within 60 minutes of where ... States or for many who are faced with health or personal issues that leave them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth ... Congress to protect parental rights and civil liberties, and to restore transparency within ... The demonstration coincides with a press conference taking place Friday morning calling on ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., a ... announce it has joined the National Association for Home Care and Hospice (NAHC), ... disabled, and dying Americans of all ages and the caregiver who provide them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... FREMONT, Calif. , March 29, 2017 /PRNewswire/ ... vision for patients as the highest standard in ... Today, Krypton Vision introduces its objective Wavefront-driven refraction ... conventional, subjective approach. This enables an unprecedented level ... optics - exceptional vision relegated to Topgun Navy ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... 2017  Maxor National Pharmacy Services, LLC ("Maxor"), a ... named Leah Bailey as General Counsel.  Bailey will ... company. With more than 13 years of ... focused on health care, Bailey joins the Maxor team ... Bailey advised the PBM, Specialty, and Mail Order business ...
Breaking Medicine Technology: